+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia



Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia



Pediatric Hematology and Oncology 16(3): 221-232



This study evaluated the efficacy of hydroxyurea treatment in the prevention of vaso-occlusive crises among children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Nineteen children and young adults with severe sickle cell disease were enrolled to the hydroxyurea treatment trial. The incidence of vaso-occlusive crises, acute chest syndrome, hemolytic crises, splenic sequestration episodes, blood transfusions, and hospital days in the 2 years before hydroxyurea (HU) treatment were compared with the same parameters in the first 2 years of treatment. The patients received a mean dose of 21.3 mg/kg/day daily and were treated during a mean period of 40.3 +/- 14 months (range 20 to 68 months). Significant increases were observed after 1 month in the Hgb, MCV, MCH, and MCHC levels and were more notable after 3 months. The increase in the Hgb F level became important after 3 months of HU therapy and was highly significant (p < .001) beyond 6 months. No differences were observed in the RDW, reticulocyte count, Hgb S, and Hgb A2. Severe neutropenia was observed in one case. A decrease in the frequency of vaso-occlusive crises, acute chest syndrome, hemolytic crises, blood transfusions, and days spent in the hospital was demonstrated during the HU treatment period compared to the same period before. The clinical and laboratory response to HU was dramatic in severely affected sickle cell anemia (SCA) patients. The response to HU in children and teenagers with severe sickle cell anemia is similar to the response in adults, and no severe adverse effects were observed.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010525880

Download citation: RISBibTeXText

PMID: 10326220

DOI: 10.1080/088800199277272


Related references

Sickle cell disease: a continuing clinical and research dilemma: Bone marrow transplantation for sickle cell disease Walters, M.C. et al. (1996) New Engl. J. Med. 335, 369376 Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial Ferster, A. et al. (1996) Blood 88, 19601961. Molecular Medicine Today 2(11): 450-451, 1996

Intriguing prevalence of benin type sickle cell gene on atypical haplotypes in sickle cell beta thalassemia but not in sickle cell anemia in sicily italy. Bank, A (Ed ) Annals Of The New York Academy Of Sciences, Vol 612 Sixth Cooley's Anemia Symposium; New York, New York, Usa, March 13-15, Xiii+590p New York Academy Of Sciences: New York, New York, Usa Illus Maps 502-503, 1990

Frequency distribution of sickle cell anemia, sickle cell trait and sickle/beta-thalassemia among anemic patients in Saudi Arabia. Journal of Natural Science, Biology, and Medicine 6(Suppl 1): S85-S88, 2015

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine 75(6): 300-326, 1996

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New England Journal of Medicine 332(20): 1317-1322, 1995

Sickle cell anemia or sickle cell anemia-thalassemia interaction? Present methods of diagnosis and their application to a case of beta-thalassodrepanocytosis. Annales des Societes Belges de Medecine Tropicale, de Parasitologie, et de Mycologie 45(2): 211-230, 1965

Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia. European Journal of Haematology 101(6): 798-803, 2018

Clinical, hematological and genetic features of sickle-cell anemia and sickle cell-beta thalassemia in a Brazilian population. Clinical Genetics 18(1): 58-64, 1980

Clinical hematologic and biosynthetic studies in sickle cell beta thalassemia a comparison with sickle cell anemia. American Journal of Hematology 1(1): 35-44, 1976

Comparison in clinical course of sickle cell-beta- thalassemia and sickle cell anemia. Blood 86(10 SUPPL 1): 656A, 1995

Sickle cell anemia, sickle cell beta-thalassemia, and thalassemia major in Albania: characterization of mutations. Human Genetics 93(2): 182-187, 1994

Splenic functions in non-negro patients with sickle-cell anemia and sickle-cell beta thalassemia. Turkish Journal of Pediatrics 21(2-4): 36-45, 1979

Immunological studies in sickle cell-beta zero thalassemia. Comparison with sickle cell anemia. Haematologica 74(6): 537-540, 1989

Neutrophil chemotaxis in sickle cell anemia sickle cell beta o thalassemia and after splenectomy. Journal of Clinical Pathology (London) 40(6): 670-672, 1987

Studies in sickle-cell anemia. VIII. Further observations on the clinical manifestations of sickle-cell anemia in children. A.M.A. American Journal of Diseases of Children 90(6): 682-691, 1955